GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (XCNQ:NOVA) » Definitions » 3-Year EPS without NRI Growth Rate

Nova Mentis Life Science (XCNQ:NOVA) 3-Year EPS without NRI Growth Rate : 27.70% (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Nova Mentis Life Science 3-Year EPS without NRI Growth Rate?

Nova Mentis Life Science's EPS without NRI for the three months ended in Mar. 2024 was C$-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 27.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 33.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Nova Mentis Life Science was 63.20% per year. The lowest was -79.10% per year. And the median was 27.10% per year.


Competitive Comparison of Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate falls into.



Nova Mentis Life Science 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Nova Mentis Life Science  (XCNQ:NOVA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Nova Mentis Life Science 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (XCNQ:NOVA) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
Executives
Derek Lloyd Harry Ivany 10% Security Holder, Director, Senior Officer